SiccaNova raises ¥1.25bn Series A to prepare XF8302 for clinical development
The financing supports manufacturing, nonclinical and regulatory work on an oral candidate for dry mouth, alongside research-team expansion.
SiccaNova Therapeutics completed a ¥1.25 billion Series A announced on September 3. Recorded participants include Tohoku University Venture Partners, JIC Venture Growth Investments, WPower Fund I, Red Capital, Shichiju Shichu Capital and Joyo Capital Partners.
The proceeds will prepare XF8302 for clinical development in xerostomia through manufacturing, quality, nonclinical and regulatory work. SiccaNova also plans to strengthen its research and business teams and explore related indications, including dry eye.
XF8302 is designed to enhance acetylcholine-driven activation of the M3 receptor. The financing advances an investigational programme focused initially on dry mouth, including cases associated with Sjögren’s syndrome.
Use of funds
Prepare clinical development of XF8302 for xerostomia
Advance manufacturing, quality, nonclinical research and regulatory work
Strengthen R&D and business teams
Explore related indications including dry eye